Grimes & Company, Inc. Cassava Sciences Inc Put Options Transaction History
Grimes & Company, Inc.
- $3.22 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
172Shares Held
11.3MCall Options Held
1.61MPut Options Held
1.43M-
Black Rock Inc. New York, NY3.05MShares$32.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.36MShares$25.4 Million0.0% of portfolio
-
State Street Corp Boston, MA1.09MShares$11.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA902KShares$9.71 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO585KShares$6.3 Million6.03% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $432M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...